Phase II dose escalation study of caspofungin for invasive Aspergillosis.
about
How to manage aspergillosis in non-neutropenic intensive care unit patientsPharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsParadoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patientsPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Dose escalation studies with caspofungin against Candida glabrata.Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosisDose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Low Caspofungin Exposure in Patients in Intensive Care Units.Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.Our 2015 approach to invasive pulmonary aspergillosis.Impact of special patient populations on the pharmacokinetics of echinocandins.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Dosing of antifungal agents in obese people.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis.[Strategies for antifungal treatment failure in intensive care units].Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia.Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence.Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with EchinocandinsInvasive Aspergillosis in Children: Update on Current Guidelines
P2860
Q26999448-DF828296-0F50-40F5-9619-54EF9FCEF8B8Q27025299-BE4EE84C-AA69-4242-BA12-AB037111B02FQ30570494-B611B209-7DDB-4F5D-89B6-48196B7D07FFQ33573788-E917F6AE-7D5C-4BA8-9F8E-EFCEFC95F345Q34532546-657BFD07-4BE6-4F33-96F4-DD78AC331980Q36376559-E1166FBC-2034-4126-B6AA-422296F9DF2FQ36757591-F4C37D00-FA28-4F28-825C-10FD526FC3E3Q36924037-B18F946F-3E7E-4223-86E0-B5072D07EBA6Q37469829-2C242C8B-095B-4604-A35D-87CD75584DFAQ37612914-F5EA1005-D0E2-4F81-9D57-1CC283A3CA10Q38314467-3178E90E-1DC7-49E5-A41B-956E2700A361Q38391049-A7FC3E32-3CBD-4C44-9805-341B218354A5Q38462784-9B352315-697C-4D44-BCC9-080D06A69081Q38586680-06BCD392-2105-4C07-BEB2-475056E85C3EQ38660761-5B299098-7ECD-4A86-BB05-C1463DD5B8A4Q38681635-33A34036-85AE-4332-81F7-A9981CB485A0Q38871233-88159C18-6A5B-4827-9843-70AFD1E131B6Q39023027-24B96E35-D9AD-429B-AA72-4AD56F8DC2C9Q41010354-010DCEC2-7A8A-4C88-BD13-E85E1D21190CQ41580172-D1689874-4E87-4E25-8002-24FDCDB037E2Q41671785-DC87AC46-1023-4EA7-8A32-7602C9B7F83AQ44583206-8DAD9F81-AFF1-4C56-B36C-1012EB408F47Q47697132-4037A219-0004-4187-BA18-8FB7F2E72108Q57746174-BFC3074D-E9C6-4F9C-822D-AB6D9A5805F7Q58775551-11296652-F0C2-48D5-980F-23065A223519
P2860
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@ast
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@en
type
label
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@ast
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@en
prefLabel
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@ast
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@en
P2093
P2860
P356
P1476
Phase II dose escalation study of caspofungin for invasive Aspergillosis.
@en
P2093
A J Ullmann
C P Heussel
F Farowski
G Würthwein
J Franklin
J J Vehreschild
P2860
P304
P356
10.1128/AAC.05134-11
P407
P577
2011-09-12T00:00:00Z